To clarify ...I'm saying that raising the cash wasn't a mistake.
What they intended to do with the investment funds didn't pan out as expected - failure can be debated at different levels here.
-------------------
With the cash ... the plan is coming together ... but it won't be quick ...
First, it was to cash up as Goodman's name allowed for it.
2nd, it was to build ROW and Israel was supposed to already be a part of ROW - oh well.
3rd, it's about optimization and growing ROW cashflow.
Then, likely more partnerships inside/outside the Americas - using the shelf prospectus to grow this - but don't expect to go to market under $12 per share - they will likely wait it out as that is this team's nature.
Then maybe a Big Pharma to take a position in our company with an option to acquire.
Then we likely sell to the partner -OR- GUD and the partner sell to a 3rd party Big Pharma based on valuations and who's willing to pay up.
Just one way to look at how it evolves - not a quick process indeed !
Selling the company at 5 to 6x sales? Sure!
That's way down the road when they've exhausted all profitable angles of ROW development.